HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Nov
22
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF MASTER SALES AGREEMENT
Nov
22
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH KEYMED BIOSCIENCE (CHENGDU) CO., LTD. FOR CM326
Nov
18
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021
Nov
08
DATE OF BOARD MEETING
Oct
21
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THIRD QUARTER OF 2021
Oct
21
REVISION OF ANNUAL CAP FOR CONTINUING CONNECTED TRANSACTIONS
Oct
15
VOLUNTARY ANNOUNCEMENT - "APIXABAN TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Sep
30
REVISION OF ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS
Sep
23
VOLUNTARY ANNOUNCEMENT - STRATEGIC ALLIANCE AGREEMENT WITH KEYMED BIOSCIENCE (CHENGDU) CO., LTD
Sep
02
VOLUNTARY ANNOUNCEMENT - NBL-015 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Sep
01
VOLUNTARY ANNOUNCEMENT - "OSELTAMIVIR PHOSPHATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Aug
26
2021 INTERIM DIVIDEND
Aug
26
2021 INTERIM RESULTS ANNOUNCEMENT
Aug
23
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH JIANGSU ALPHAMAB FOR THE DEVELOPMENT AND COMMERCIALIZATION OF KN026 IN CHINA
Aug
19
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2021
Aug
17
VOLUNTARY ANNOUNCEMENT - STRATEGIC PARTNERSHIP AND LICENSE AGREEMENT WITH FLAME BIOSCIENCES
Aug
16
DATE OF BOARD MEETING
Aug
09
VOLUNTARY ANNOUNCEMENT - "AFATINIB DIMALEATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Jul
16
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE "SYSA1801" OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jun
25
VOLUNTARY ANNOUNCEMENT - "TOFACITINIB CITRATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Jun
16
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE "SYSA1801" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jun
09
VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "SIROLIMUS FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL
Jun
08
VOLUNTARY ANNOUNCEMENT - "PREGABALIN CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
May
31
VOLUNTARY ANNOUNCEMENT - "LACOSAMIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
25
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE CDK9 INHIBITOR "SYHX1903" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
May
25
VOLUNTARY ANNOUNCEMENT - "LINAGLIPTIN TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
25
VOLUNTARY ANNOUNCEMENT - NBL-015 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
May
24
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2021
May
20
VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1811 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
May
18
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 18 MAY 2021
May
11
DATE OF BOARD MEETING
May
11
VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
11
VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION"
May
11
VOLUNTARY ANNOUNCEMENT - "SORAFENIB TOSYLATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
11
VOLUNTARY ANNOUNCEMENT - "ALOGLIPTIN BENZOATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
May
07
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL FIRST-IN-CLASS PRODUCT SYSA1801 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Apr
30
CONNECTED TRANSACTION - DISPOSAL OF 49.5% EQUITY INTEREST IN JOINT VENTURE COMPANY /CONTINUING CONNECTED TRANSACTIONS - MASTER PURCHASE AGREEMENT
Apr
26
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2021
Apr
23
VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Apr
19
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING APPROVAL OF "DUVELISIB CAPSULES" ACCEPTED BY NMPA
Apr
14
NOTICE OF ANNUAL GENERAL MEETING
Apr
09
INVESTIGATIONAL NEW DRUG NBL-015 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Apr
01
VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Mar
30
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)"
Mar
29
VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
25
VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
16
VOLUNTARY ANNOUNCEMENT - DUAL INHIBITOR JAK-SyK "SYHX1901" OBTAINS CLINICAL TRIAL APPROVAL
Mar
15
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020
Mar
10
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Mar
09
VOLUNTARY ANNOUNCEMENT - PRODUCT LICENSING AND COMMERCIALIZATION AGREEMENT
Mar
09
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Mar
05
APPOINTMENT AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS
Mar
05
POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 5 MARCH 2021
Mar
04
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 December 2020
Mar
03
DATE OF BOARD MEETING
Feb
07
NOTICE OF 2021 FIRST EXTRAORDINARY GENERAL MEETING
Feb
01
PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE PROPOSED AMENDMENTS TO ARTICLES OF ASSOCIATION
Jan
27
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Jan
27
APPOINTMENT AND RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE OF BOARD COMMITTEE S
Jan
08
VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2021 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer